Alpha DNA Investment Management LLC Purchases Shares of 9,626 Omnicell, Inc. (NASDAQ:OMCL)

Alpha DNA Investment Management LLC purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 9,626 shares of the company's stock, valued at approximately $429,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its stake in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp increased its stake in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC bought a new stake in shares of Omnicell during the fourth quarter worth $53,000. First Horizon Advisors Inc. boosted its stake in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the period. Finally, Huntington National Bank grew its holdings in shares of Omnicell by 236.4% in the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after purchasing an additional 955 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wells Fargo & Company lowered their price objective on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, April 15th. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Bank of America decreased their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Finally, Benchmark reiterated a "buy" rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of "Hold" and an average target price of $50.67.

Omnicell Stock Up 1.7 %

NASDAQ OMCL traded up $0.54 on Thursday, hitting $31.23. The stock had a trading volume of 175,008 shares, compared to its average volume of 524,273. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The business's fifty day moving average price is $34.67 and its 200 day moving average price is $41.03. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of 115.68, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.